Patient Information Leaflet in accordance with the Pharmacists Regulations (Preparations) 1986

The medicine is dispensed with a doctor's prescription only

Fulvestrant 250 mg S.K.

Injection Solution for Intramuscular injection in a ready-to-use syringe

Composition:

Fulvestrant 50mg/ml

Each (5ml) ready-to-use syringe contains:

Fulvestrant 250 mg

For the list of inactive ingredients in this preparation, see Section 2 "important information regarding some of medicine ingredients" and section 6 - "Additional information"

Read the leaflet carefully in its entirety before using the medicine.

Keep the leaflet as you may need it again.

This leaflet contains concise information about the medicine. If you have additional questions, consult the doctor or pharmacist.

This medicine was prescribed for the treatment of your disease. Do not pass it on to others. It may harm them even if it seems to you that their disease is similar.

1. What is the medicine intended for?

- Fulvestrant is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, or with disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy.
- Combination Therapy with Palbociclib:

Fulvestrant is indicated for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)- negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy When using Fulvestrant S.K. combined with Palbociclib (Ibrance), please also read the Patient Information Leaflet for Palbociclib (Ibrance).

Therapeutic group:

Estrogen antagonist.

The drug Fulvestrant S.K. contains the active ingredient Fulvestrant, which belongs to the group of medicines that block the activity of estrogen. Estrogen is a female sex hormone, which in some cases can be involved in the development of breast cancer.

2. Before using the medication

Do not use the medication if:

- if you are allergic to fulvestrant or to any of the other ingredients of this medicine (listed in section 6)
- if you are pregnant or breast-feeding
- if you have severe liver problems

Special warnings regarding the use of Fulvestrant S.K.

Before taking the medicine tell your doctor if you have any:

- Kidney or liver problems.
- Previous problems with blood clotting.
- Low level of platelets in the blood (help to clot the blood) or bleeding disorders.
- Osteoporosis (thinning of the bone).
- Alcohol addiction (alcoholism).
- This medication may interfere with the results of tests that measure estradiol levels. The doctor should be informed that you are taking Fulvestrant S.K. in any referral for laboratory tests.

Children and adolescents

Fulvestrant S.K. is not indicated for use in girls and adolescents under 18 years of age.

_ Drug-drug interactions/reactions

If you are taking or have recently taken other medications including non-prescription drugs and food supplements, tell the doctor or pharmacist about that, particularly if you are taking:

Please inform the treating physician if you are taking additional medications at the same time or if you have just finished treatment with another drug, including over-the-counter medicines, vitamins, food supplements and medicinal herbs. This is because Fulvestrant

S.K. may affect the way some medicines work, and, in turn, some medicines may affect the way Fulvestrant S.K. works, especially anticoagulants.

_ Pregnancy and breastfeeding

- **Pregnancy :**

Do not use Fulvestrant S.K. if you are pregnant. If you are of childbearing potential and you could become pregnant, you must use effective contraception during the period of treatment with Fulvestrant S.K. and for two years after receiving the last dose of the treatment.

- **Breastfeeding :**

Do not breast-feed during treatment with Fulvestrant S.K.

Driving and using machinery

Fulvestrant S.K. should not affect your ability to drive or use machines. If you feel tired as a result of the treatment, do not drive or operate machinery.

Important information on some of the ingredients

Fulvestrant S.K. contains 10% w/v (weight per volume) ethanol (alcohol), for example a 500 mg of alcohol per dose which is equivalent to a 10 ml serving of beer or an 4 ml serving of wine. This amount can harm those who suffer from alcohol addiction. This should be taken into consideration at risk people; such as patients with liver disease or epilepsy.

Fulvestrant S.K. contains 500 mg of benzyl alcohol per injection, equivalent to 100 mg/ml. Benzyl alcohol can lead to allergic reactions.

Fulvestrant S.K. contains 750 mg of benzyl benzoate per injection, equivalent to 150 mg/ml.

3. How should you use the drug?

Always use this medication according to the doctor's instructions. If you are not sure, always check with the doctor or pharmacist.

The doctor will tell you how to take the medicine (how much and when to inject). The strength and duration of treatment are determined by the doctor according to the disease you are suffering from.

The usual dose in the absence of any other instruction from the doctor is:

The usual dose is 500 mg of Fulvestrant (2 injections of 250 mg/5 ml) given once a

month, and in addition, a dose of 500 mg given two weeks after the first dose.

- When Fulvestrant is given in combination with Ibrance, the usual dose of Fulvestrant is 500 mg on days 1, 15 and 29, and once a month thereafter. Please consult the patient information leaflet for Ibrance.

Instructions for use

Your doctor or nurse will inject you with the **Fulvestrant S.K.** by using slow intramuscular injection. One shot to each side of the buttocks.

If, by mistake, you have taken an excess dose or if a child has accidentally swallowed some of the drug, refer immediately to a doctor or hospital emergency room and take the package of the medicine with you.

You must complete the treatment recommended by your doctor.

Even if your health improves, do not stop treatment with the medicine without consulting the doctor.

Care should be taken to follow the instructions for taking the medicine accurately and the doctor should be consulted in the case of any doubt.

Do not take medicines in the dark! Check the label and the dose <u>each time</u> you take medicine. Wear glasses if you need them.

If you have any further questions regarding the use of this medicine, consult with your doctor or pharmacist.

4. <u>Side effects</u>

As with any drug, the use of Fulvestrant S.K. may cause side effects in some users. Do not panic when reading the list of side effects. You may not experience any of them.

Side effects that require special attention:

You may need urgent medical attention if the following side effects occur:

Fulvestrant S.K. as a single treatment:

- Hypersensitivity reaction (allergy), including swelling of the face, lips, tongue and/or throat. These may be signs of anaphylactic reactions.
- Thromboembolism - an increased risk of blood clots*.
- Liver inflammation (hepatitis).
- Liver failure.

Fulvestrant S.K. in combination with Palbociclib:

- pulmonary embolism

Report to your doctor or pharmacist if the following side effects appear:

Very common Side effects (affecting more than 1 in 10 patients):

Fulvestrant S.K. as a single treatment:

- Reactions at the injection site, such as pain and/or inflammation.
- Abnormal levels of liver enzymes (in blood tests)*.
- Nausea.
- Weakness.
- Tiredness*.
- Joint and musculoskeletal Pain.
- Hot flushes.
- Skin rash.
- Hypersensitivity reaction (allergy), including swelling of the face, lips, tongue and/or throat.

Additional side effects:

Common Side effects (affecting up to 1 in 10 patients):

- Headache.
- Vomiting, diarrhea or loss of appetite*.
- Urinary tract infection.
- Back pain*.
- Thromboembolism - an increased risk of blood clots*.
- An increase in the level of bilirubin (bile pigment produced by the liver).
- Decreased levels of platelets in the blood (thrombocytopenia).
- Vaginal bleeding.
- Lower back pain radiating to the leg on one side (sciatica).
- Sudden weakness, numbness, tingling or loss of movement in the legs, especially only on one side of the body, sudden problem with the ability to walk or keep balance (peripheral neuropathy).

Fulvestrant S.K. in combination with Palbociclib:

Very common side effects (affects at least 1 in 10 patients):

- A decrease in the number of white blood cells (neutropenia, leukopenia).
- Infections.
- Tiredness.
- Nausea , vomiting.
- Anemia.
- Mouth inflammation (stomatitis).
- Headache.
- Diarrhea.
- A decrease in the number of platelets in the blood (thrombocytopenia).
- Constipation.
- Balding.
- Rash.
- Decreased appetite.
- Fever.

Additional side effects :

- Weakness.

Fulvestrant S.K. as a single treatment

Uncommon side effects (affects up to 1 patient in 100):

- Thick and white discharge from the vagina and fungal infection.
- Bruising, bleeding at the injection site.
- An increased level of liver enzymes called gamma GT (in blood tests).
- Liver inflammation (hepatitis).
- Liver failure.
- Tingling, numbness and pain.
- Anaphylactic reaction (allergy)

  * Includes side effects in which the effect of Fulvestrant S.K. is unclear, due to the background disease.

  If a side effect appears, if one of the side effects worsens, or if you suffer from

a side effect not mentioned in the leaflet, please consult the doctor.

Reporting side effects

Side effects can be reported to the Ministry of Health by clicking the link "Report Side Effects of Drug Treatment" available on the Ministry of Health homepage (www.health.gov.il) that directs to the online form for reporting side effects, or by clicking the link:

https://sideeffects.health.gov.il/

5. How to store the medicine?

- Prevent poisoning! This medicine and any other medicine should be kept in a closed place out of the reach and sight of children and/or infants to avoid poisoning.
- Do not induce vomiting without explicit instruction from the doctor.
- Store in a refrigerator at 2°C - 8°C.
- Store the Fulvestrant S.K. in the original package to protect from light.
- Do not use the medicine after the expiry date (exp. date) appearing on the package. The expiry date refers to the last day of that month. If in doubt, consult the pharmacist who dispensed the medicine to you.

6. Additional information

In addition to the active ingredient, the medicine also contains:

Benzyl benzoate, benzyl alcohol, ethanol 96%, castor oil.

What does the medicine look like?

- Fulvestrant S.K. is a clear, transparent to yellow, viscous solution for injection, contained in a pre-filled syringe with a safety cap.
- Each package contains one, or two, or four, or six glass syringes, ready-to-use, and safety needles (BD SurGuard®) to attach to each syringe.
- It is possible that not all package sizes are marketed.

Manufacturer:

DR. REDDY'S LABORATORIES LIMITED, INDIA

8-2-337, ROAD NO. 3, BANJARA HILLS, HYDERABAD–500034, TELANGANA, INDIA.

Registration holder and importer:

K.S. Kim International Ltd., 94 Yigal Alon Street, Tel-Aviv-Jaffa, 6789139.

Drug's registration number in the State Drug Registry at the Ministry of Health:

165-13-35691

Revised in October 2022 according to MOH guidelines.

KS_FULV_PIL_12_2020_V02